FRAT1 Antikörper (AA 161-260) (HRP)

Produktnummer ABIN1712053

Produktdetails anti-FRAT1 Antikörper (HRP)

Target: FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))

Bindungsspezifität: AA 161-260

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser FRAT1 Antikörper ist konjugiert mit HRP

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Homologie: Human,Mouse,Rat,Dog,Cow

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human FRAT1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handhabung: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu FRAT1

Target: FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))

Andere Bezeichnung: FRAT1 (FRAT1 Produkte)

Synonyme: FRAT1 antikoerper, frat1 antikoerper, AW060382 antikoerper, gbp antikoerper, FRAT1, WNT signaling pathway regulator antikoerper, GSK-3 binding protein FRAT1 antikoerper, frequently rearranged in advanced T cell lymphomas antikoerper, frequently rearranged in advanced T-cell lymphomas antikoerper, frequently rearranged in advanced T-cell lymphomas 1 S homeolog antikoerper, FRAT1 antikoerper, frat1 antikoerper, Frat1 antikoerper, frat1.S antikoerper

Hintergrund:

Synonyms: FRAT 1, frequently rearranged in advanced T cell lymphomas, Frequently rearranged in advanced T-cell lymphomas, GSK 3 binding protein FRAT1, proto oncogene FRAT1, FRAT1_HUMAN.

Background: FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.

Gen-ID: 10023